Skip to main content

Advertisement

Log in

JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma—overview

International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Center for Cancer Control and Information Services of the National Cancer Center: ganjoho.jp. http://ganjoho.jp/reg_stat/index.html.

  2. Jsffe ES. Introduction and over view of the classification of lymphoid neoplasms. In: Swerdlow SH, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017. p. 190–8 (Textbook).

    Google Scholar 

  3. Chan JK. The new World Health Organization classification of lymphomas: the past, the present and the future. Hematol Oncol. 2001;19(4):129–50.

    Article  CAS  PubMed  Google Scholar 

  4. Carbone PP, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31(11):1860–1.

    CAS  PubMed  Google Scholar 

  5. Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Rohatiner A, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5(5):397–400.

    Article  CAS  PubMed  Google Scholar 

  7. Shipp MA. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94 (3iA).

    Article  Google Scholar 

  8. Zhou Z, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42 (3iA)..

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Solal-Céligny P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65 (3iA).

    Article  CAS  PubMed  Google Scholar 

  10. Hasenclever D, et al. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–14 (3iiiDiii).

    Article  CAS  PubMed  Google Scholar 

  11. Federico M, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–62 (3iDiii).

    Article  PubMed  Google Scholar 

  12. Cheson BD, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17(4):1244–53.

    Article  CAS  PubMed  Google Scholar 

  13. Cheson BD, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.

    Article  PubMed  Google Scholar 

  14. Juweid ME, et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol. 2005;23(21):4652–61 (3iiiDiii).

    Article  PubMed  Google Scholar 

  15. Barrington SF, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–58.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Weeks JC, et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991;9(7):1196–203 (3iiiD).

    Article  CAS  PubMed  Google Scholar 

  17. Oh YK, et al. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology. 1999;210(2):483–6 (3iiiD).

    Article  CAS  PubMed  Google Scholar 

  18. Liedtke M, et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol. 2006;17(6):909–13 (3iiiA).

    Article  CAS  PubMed  Google Scholar 

  19. Jerusalem G, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol. 2003;14(1):123–30 (3iiiD).

    Article  CAS  PubMed  Google Scholar 

  20. Zinzani PL, et al. Role of fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27(11):1781–7 (3iiiD).

    Article  PubMed  Google Scholar 

  21. Hiniker SM, et al. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era. Int J Radiat Oncol Biol Phys. 2015;92(1):99–106.

    Article  PubMed  Google Scholar 

  22. Huntington SF, et al. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol. 2015;33(13):1467–74.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ken Omachi.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Omachi, K. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma—overview. Int J Hematol 110, 3–10 (2019). https://doi.org/10.1007/s12185-019-02676-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-019-02676-0

Navigation